


In the Claims:


Please cancel claims 2 to 52 without prejudice or disclaimer. Please add new claims 53 to 83, as follows:

53. (NEW) A compound or a pharmaceutically acceptable salt of the compound, wherein the compound has the structure:



wherein:


- (i)  $R^1$  is a group:



wherein  $X_d$  is H; and,  $X_e$  is Cl or Br;

or:

- (ii)  $R^1$  is a group:




wherein  $X_d$  and  $X_e$  are independently the same or different and are selected from Cl, Br, I, and CN;

or:

- (iii)  $R^1$  is a group:


wherein Q is:



wherein each  $R^6$  is independently -H, -OH, -OC(=O)CH<sub>3</sub>, or F; and,  
 $R^7$  is -H, a phosphate group, a phosphodiester group, or a phosphoramidate group;  
 wherein the compound may be in any enantiomeric, diastereomeric, or  
 stereoisomeric form, including D-form, L-form,  $\alpha$ -anomeric form, and  $\beta$ -anomeric form.


54. (NEW) A compound according to claim 53, wherein:

$R^1$  is a group:




wherein  $X_d$  is H; and,  $X_e$  is Cl or Br.

55. (NEW) A compound according to claim 53, having the structure:




56. (NEW) A compound according to claim 53, having the structure:



57. (NEW) A compound according to claim 53, wherein:


$R^1$  is a group:



wherein  $X_d$  and  $X_e$  are independently the same or different and are selected from  
 Cl, Br, I, and CN.

58. (NEW) A compound according to claim 53, wherein:

$R^1$  is a group:




wherein each X is selected from Cl, Br, I, and CN.


59. (NEW) A compound according to claim 58, wherein X is Cl or Br.

60. (NEW) A compound according to claim 58, wherein X is Br.


61. (NEW) A compound according to claim 53, wherein Q is:




62. (NEW) A compound according to claim 53, wherein Q is:




63. (NEW) A compound according to claim 53, having the structure:




64. (NEW) A compound according to claim 53, having the structure:




65. (NEW) A compound according to claim 53, wherein  $R^7$  is -H.
66. (NEW) A compound according to claim 53, wherein  $R^7$  is a phosphoramidate group derived from an amino acid.
67. (NEW) A compound according to claim 53, wherein  $R^7$  is:



68. (NEW) A compound according to claims 53, wherein  $R^7$  is:




69. (NEW) A compound according to claim 53, having the structure:




wherein  $X_d$  is H; and,  $X_e$  is Cl or Br.

70. (NEW) A compound according to claim 53, having the structure:




wherein  $X_d$  is H; and,  $X_e$  is Cl or Br.


71. (NEW) A compound according to claim 53, having the structure:



72. (NEW) A compound according to claim 53, having the structure:




73. A compound according to claim 53, having the structure:



wherein  $X_d$  and  $X_e$  are independently the same or different and are selected from Cl, Br, I, and CN.

74. (NEW) A compound according to claim 53, having the structure:



wherein each X is selected from Cl, Br, I, and CN.

75. (NEW) A composition comprising a compound according to claim 53 and a carrier.
76. (NEW) A composition comprising a compound according to claim 53, and a pharmaceutically acceptable carrier.

77. (NEW) A method for screening for a therapeutic agent, comprising:
- (a) contacting a sample containing a target cell with a compound according to claim 53;
  - (b) contacting a separate sample of the target cell with a potential therapeutic agent; and
  - (c) comparing the samples for inhibition of cellular proliferation or cell killing.
78. (NEW) A method according to claim 77, wherein the target cell is characterized as resistant to a chemotherapeutic drug.
79. (NEW) A method according to claim 77, wherein the target cell is characterized as expressing a target enzyme that is amplified as a result of selection *in vivo* by chemotherapy.
80. (NEW) A method according to claim 77, wherein the target enzyme is an endogenous intracellular enzyme that is overexpressed in the target cell.
81. (NEW) A method for inhibiting the proliferation of a pathological cell, wherein thymidylate synthase is overexpressed in the cell, comprising contacting the cell with an effective amount of the compound according to claim 53.
82. (NEW) A method according to claim 81, wherein the pathological cell is a colon cancer cell, a breast cancer cell, a gastric cancer cell, a head and neck cancer cell, a liver cancer cell, or a pancreatic cancer cell.
83. (NEW) A method according to claim 81, wherein the pathological cell is a colon cancer cell.